Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Semler Scientific, Inc. (Nasdaq: SMLR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents cover both its healthcare operations and its Bitcoin treasury activities, offering investors insight into how the company reports revenues and expenses from its medical device and software business alongside unrealized gains and losses from changes in the fair value of its Bitcoin holdings.
In its periodic reports, Semler Scientific presents financial statements that reflect income from operations in its healthcare segment, operating expenses such as engineering and product development, sales and marketing, and general and administrative costs, as well as line items related to digital assets. The filings detail the fair value of Bitcoin classified as intangible digital assets, changes in that fair value, and the impact on pre-tax income. They also describe capital-raising transactions, including at-the-market equity offering programs and 4.25% convertible senior notes due 2030, and provide information on stockholders’ equity.
Current reports on Form 8-K document material events such as the adoption and evolution of Semler Scientific’s Bitcoin treasury strategy, the master loan agreement with Coinbase Credit Inc. secured by Bitcoin collateral, and the agreement in principle to settle a civil investigative demand from the U.S. Department of Justice. Other 8-K filings describe a strategic plan to realign operations through headcount reductions and expense curtailment, a non-executive retention program, executive officer changes and the Agreement and Plan of Merger providing for the acquisition of Semler Scientific by Strive, Inc. in an all-stock transaction.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as segment performance, digital asset disclosures, capital structure changes and merger-related information. Investors can also use the filings to monitor topics like BTC Yield as a disclosed key performance indicator, the structure of Bitcoin-related financing arrangements and other regulatory disclosures relevant to SMLR.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. (SMLR). The notice emphasizes forward-looking statement cautions and references Strive’s Form S-4, which registers Class A common stock to be issued in connection with the transaction. A combined Information Statement/Proxy Statement/Prospectus will be provided to Semler Scientific stockholders to seek their approval.
Investors are directed to read the Registration Statement and related materials when available, accessible free of charge on the SEC’s website and each company’s investor relations pages. The communication also notes that directors and officers of both companies may be deemed participants in the proxy solicitation, with their interests to be described in the forthcoming joint materials. It reiterates a standard no offer or solicitation disclaimer, stating that any sale of securities will occur only by means of a prospectus meeting Securities Act requirements.
Strive, Inc. reposted a communication on X regarding its proposed business combination with Semler Scientific. The message emphasizes that any forward-looking statements involve risks and uncertainties.
Strive has filed a Form S‑4 to register Class A common stock to be issued in the transaction, and an Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek approval. Investors are urged to read the Registration Statement and related materials when available on the SEC website. This communication does not constitute an offer to sell securities.
Strive, Inc. and Semler Scientific announced a proposed business combination. Strive has filed a Form S-4 to register the Class A common stock it would issue in the transaction. The combined information statement, proxy statement, and prospectus will be sent to Semler Scientific stockholders to seek their approval.
The communication includes a standard caution that any forward-looking statements involve risks and uncertainties, and references each company’s SEC filings for additional risk factors. It also notes that directors, officers, and employees of both companies may be deemed participants in the proxy solicitation.
This is not an offer or solicitation to buy or sell securities. Investors can access the Registration Statement and related materials free of charge at the SEC’s website and the companies’ investor relations pages.
Strive, Inc. filed a communication under Rule 425 regarding its proposed business combination with Semler Scientific (SMLR). Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement for Strive, a proxy statement for Semler Scientific, and a prospectus for Strive.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The communication includes forward-looking statement cautions and states it is not an offer or solicitation to buy or sell securities.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. (SMLR). The notice reiterates cautionary forward‑looking statements language and directs investors to SEC filings for details.
Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, which will include a combined Information Statement/Proxy Statement/Prospectus. A definitive version will be sent to Semler stockholders to seek approval of the transaction.
The communication emphasizes that it is not an offer or solicitation and that sales can occur only via a prospectus meeting Section 10 of the Securities Act or an applicable exemption. Investors are urged to read the S‑4 and related materials when available on the SEC’s website and the companies’ investor sites.
Strive, Inc. filed a communication under Rule 425 regarding its proposed business combination with Semler Scientific (SMLR). The notice, reposted by a Strive director on X.com, includes a forward‑looking statements caution and directs investors to upcoming proxy materials.
Strive has filed a Form S‑4 to register Class A common stock to be issued in the transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. Documents will be available free of charge on the SEC’s website and each company’s investor site. The communication states it is not an offer or solicitation to buy or sell securities.
Strive, Inc. announced a proposed business combination with Semler Scientific via a Form 425 communication referencing a post on X.com dated November 10, 2025. Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction, and Semler Scientific stockholders will receive an information statement/proxy statement/prospectus to consider and vote on the deal. The communication includes extensive forward-looking statement cautions and directs investors to SEC filings for details. It also states this is not an offer or solicitation to sell securities.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive has filed a Form S-4 to register the Class A common stock to be issued in the transaction, which will include an information statement, proxy statement, and prospectus.
Semler Scientific stockholders will receive a definitive proxy/prospectus to vote on the deal. The communication includes forward‑looking statement cautions, explains how to access SEC filings, notes potential proxy “participants,” and clarifies it is not an offer to sell or solicit securities.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific, Inc. (SMLR). Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in connection with the transaction. A combined information statement/proxy statement/prospectus will be sent to Semler Scientific stockholders to seek their approval.
The communication includes forward-looking statement cautions and directs investors to the SEC’s website and company investor pages for the Registration Statement and related materials when available.
Strive, Inc. released a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR), which was reposted on X.com by board member Pierre Rochard on November 10, 2025.
Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction. The S-4 includes an information statement/proxy statement/prospectus, and a definitive version will be sent to Semler stockholders to seek their approval.
The notice includes forward‑looking statement cautions, directs investors to the SEC and company websites for documents, identifies potential proxy solicitation participants, and states it is not an offer or solicitation.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
